Delivery of bone morphogenetic protein-2 and substance P using graphene oxide for bone regeneration

International Journal of Nanomedicine

Volumn 9, Issue SUPPL.1, 2014, Pages 107-116

  La, Wan Geun ^a   Jin, Min ^a   Park, Saibom ^a   Yoon, Hee Hun ^a   Jeong, Gun Jae ^a   Bhang, Suk Ho ^a   Park, Hoyoung ^a   Char, Kookheon ^a   Kim, Byung Soo ^a  

^a Seoul National University   (South Korea)

Author keywords

Bone morphogenetic protein 2; Bone regeneration; Graphene oxides; Stem cell recruitment; Substance P

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; GRAPHENE OXIDE; SUBSTANCE P; TITANIUM; GRAPHITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; CALVARIA; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOLOGY; IMPLANT; IN VITRO STUDY; MATERIAL COATING; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; MESENCHYMAL STROMA CELL; PROCEDURES; PROSTHESES AND ORTHOSES; SKULL;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; DRUG DELIVERY SYSTEMS; GRAPHITE; MESENCHYMAL STROMAL CELLS; MICE; PROSTHESES AND IMPLANTS; SKULL; SUBSTANCE P;

EID: 84900405009     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S50742     Document Type: Article

References (41)

1. Reddi AH. BMPs: from bone morphogenetic proteins to body morphogenetic proteins. Cytokine Growth Factor Rev. 2005;16(3):249-250.
2. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2(2-3):81-96.
3. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg. 2007;77(8):626-631.
4. Termaat MF, Den Boer FC, Bakker FC, Patka P, Haarman HJ. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am. 2005;87(6):1367-1378.
5. Govender S, Csimma C, Genant HK, et al; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84-A(12):2123-2134.
6. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery. Biotechnol Lett. 2009;31(12): 1817-1824.
7. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 2002;27(16 Suppl 1):S40-S48.
8. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006;31(5):542-547.
9. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2(2-3):81-96.
10. Takahashi Y, Yamamoto M, Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials. 2005;26(23):4856-4865.
11. Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, Kim BS. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A. 2010;16(4):1225-1233.
12. Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells. 2008;26(1):223-234.
13. Ko IK, Ju YM, Chen T, Atala A, Yoo JJ, Lee SJ. Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration. FASEB J. 2012;26(1):158-168.
14. Hylden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 1981;217(1): 212-215.
15. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201(2):167-180.
16. Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci U S A. 1994;91(19):8964-8968.
17. Nakamura M, Kawahara M, Morishige N, Chikama T, Nakata K, Nishida T. Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1. Diabetologia. 2003;46(6):839-842.
18. Kohara H, Tajima S, Yamamoto M, Tabata Y. Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials. 2010;31(33):8617-8625.
19. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990;40(2):264-278.
20. Hong HS, Lee J, Lee E, et al. A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med. 2009;15(4):425-435.
21. Carlsson O, Schizas N, Li J, Ackermann PW. Substance P injections enhance tissue proliferation and regulate sensory nerve ingrowth in rat tendon repair. Scand J Med Sci Sports. 2011;21(4):562-569.
22. Lucas LC, Lacefield WR, Ong JL, Whitehead RY. Calcium phosphate coatings for medical and dental implants. Colloids Surf A Physicochem Eng Asp. 1993;77(2):141-147.
23. Thomas KA, Kay JF, Cook SD, Jarcho M. The effect of surface macrotexture and hydroxylapatite coating on the mechanical strengths and histologic profiles of titanium implant materials. J Biomed Mater Res. 1987;21(12):1395-1414.
24. Maxian SH, Zawadsky JP, Dunn MG. In vitro evaluation of amorphous calcium phosphate and poorly crystallized hydroxyapatite coatings on titanium implants. J Biomed Mater Res. 1993;27(1):111-117.
25. Le Guéhennec L, Soueidan A, Layrolle P, Amouriq Y. Surface treatments of titanium dental implants for rapid osseointegration. Dent Mater. 2007;23(7):844-854.
26. Kim SE, Song SH, Yun YP, et al. The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast function. Biomaterials. 2011;32(2): 366-373.
27. Bae SE, Choi J, Joung YK, Park K, Han DK. Controlled release of bone morphogenetic protein (BMP)-2 from nanocomplex incorporated on hydroxyapatite-formed titanium surface. J Control Release. 2012;160(3):676-684.
28. La WG, Park S, Yoon HH, et al. Delivery of a therapeutic protein for bone regeneration from a substrate coated with graphene oxide. Small. Epub July 10, 2013.
29. Hong J, Shah NJ, Drake AC, et al. Graphene multilayers as gates for multi-week sequential release of proteins from surfaces. ACS Nano. 2012;6(1):81-88.
30. Ruiz ON, Fernando KA, Wang B, et al. Graphene oxide: a nonspecific enhancer of cellular growth. ACS Nano. 2011;5(10):8100-8107.
31. Weber D, Kotzsch A, Nickel J, et al. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol. 2007;7:6.
32. Mücksc C, Urbassek HM. Adsorption of BMP-2 on a hydrophobic graphite surface: a molecular dynamics study. Chem Phys Lett. 2011;510(4-6):252-256.
33. Utesch T, Daminelli G, Mroginski MA. Molecular dynamics simulations of the adsorption of bone morphogenetic protein-2 on surfaces with medical relevance. Langmuir. 2011;27(21):13144-13153.
34. Park S, Bhang SH, La WG, Seo J, Kim BS, Char K. Dual roles of hyaluronic acids in multilayer films capturing nanocarriers for drug-eluting coatings. Biomaterials. 2012;33(21):5468-5477.
35. Jang Y, Park S, Char K. Functionalization of polymer multilayer thin films for novel biomedical applications. Korean J Chem Eng. 2011;28(5):1149-1160.
36. Hur J, Yang HM, Yoon CH, et al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation. 2007;116(15):1671-1682.
37. Farhat YM, Al-Maliki AA, Chen T, et al. Gene expression analysis of the pleiotropic effects of TGF-β1 in an in vitro model of flexor tendon healing. PLoS ONE. 2012;7(12):e51411.
38. Freilich M, Patel CM, Wei M, et al. Growth of new bone guided by implants in a murine calvarial model. Bone. 2008;43(4):781-788.
39. Shahdadfar A, Frønsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells. 2005;23(9):1357-1366.
40. Hildebrandt C, Büth H, Thielecke H. Influence of cell culture media conditions on the osteogenic differentiation of cord blood-derived mesenchymal stem cells. Ann Anat. 2009;191(1):23-32.
41. Hong HS, Kim do Y, Yoon KJ, Son Y. A new paradigm for stem cell therapy: substance-P as a stem cell-stimulating agent. Arch Pharm Res. 2011;34(12):2003-2006.